免疫治疗相关生物标志物：确认和不确定性。
Immunotherapy-Related Biomarkers: Confirmations and Uncertainties.
发表日期：2023 Sep 15
作者：
Martina Catalano, Luigi Francesco Iannone, Gabriella Nesi, Stefania Nobili, Enrico Mini, Giandomenico Roviello
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
摘要：
免疫疗法深刻改变了肿瘤学治疗，成为主要治疗策略之一。在生存结果方面取得了显著改善，但从免疫疗法中受益的患者比例仍有限。只有三分之一接受免疫检查点抑制剂（ICIs）的患者能够实现长期反应。有些患者对治疗无反应或在初次反应后复发。到目前为止，程序性死亡配体1、微卫星不稳定性和肿瘤突变负担是已验证的三种预测ICIs反应的生物标志物，但单一变量似乎仍不足以选择患者。考虑到这些药物的广泛和日益增加的使用，寻找新的ICIs反应预测生物标志物至关重要。我们总结了肿瘤学中免疫生物标志物的现状和临床应用，突出了目前已批准的生物标志物的优势和不足，描述了新兴的组织和循环生物标志物，并概述了未来的展望。版权所有 © 2023作者。由Elsevier B.V.出版。保留所有权利。
Immunotherapy profoundly changed oncology treatment, becoming one of the main therapeutical strategies. Remarkable improvement has been achieved in survival outcomes, but the percentage of patients who benefit from immunotherapy is still limited. Only one-third of patients receiving immune checkpoint inhibitors (ICIs) achieve long-term response. Several patients are not responsive to treatment or relapse after an initial response. To date, programmed death-ligand 1, microsatellite instability, and tumor mutational burden are the three biomarkers validated to predict the ICIs response, but a single variable seems still insufficient in the patient's selection. Considering the substantial and increasing use of these drugs, the identification of new predictive biomarkers of ICI response is of paramount importance. We summarize the state of the art and the clinical use of immune biomarkers in oncology, highlighting the strength and weaknesses of currently approved biomarkers, describing the emerging tissues and circulating biomarkers, and outlining future perspectives.Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.